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Abstract Interferon-Q (IFN-Q), a multifunctional cytokine, has
been noted as a potential therapeutic agent for various fibrotic
disorders, including excessive scar tissue formation. We pre-
viously reported that transforming growth factor-L1 (TGF-L1)
induced the myofibroblastic phenotype in palatal fibroblasts
derived from palatal mucosa, and that such effects might have a
close link to palatal scar formation. In the present study, we
examined the effects of IFN-Q on TGF-L1-pretreated palatal
fibroblasts for the purpose of clarifying the suppressive potency
against myofibroblastic phenotype expression in vitro. IFN-Q
significantly altered the spindle morphology of TGF-L1-pre-
treated palatal fibroblasts into the polygonal one that was similar
to the non-treated palatal fibroblasts. This change was parallel
with a decrease in the expression of K-smooth muscle actin
protein, a marker for myofibroblast, as determined by immuno-
blot analysis. Northern blot analysis showed that IFN-Q inhibited
proK2(I) collagen mRNA expression that was stimulated by
TGF-L1 pretreatment for 24 h. Furthermore, IFN-Q decreased
the cell contractility enhanced by TGF-L1 pretreatment for 24 h
in a three-dimensional collagen gel culture system. These results
suggest that IFN-Q may have negative effects with regard to
controlling the myofibroblastic phenotype induced by TGF-L1 in
palatal fibroblasts.
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1. Introduction
A myo¢broblast is a ¢broblast subtype that possesses char-
acteristics between those of ¢broblasts and smooth muscle
cells. Gabbiani et al. [1] have described that myo¢broblasts
exhibit several ultrastructural features of smooth muscle cells,
including the presence of nuclear folds, abundant cytoplasmic
micro¢laments with dense bodies, complex cellular junctions,
and micro¢lament bundles. Myo¢broblasts appear in granu-
lation tissue during the dermal wound healing process, and
they are considered to function during wound contraction [2]
as well as during the accumulation of extracellular matrix
components including type I collagen [3]. K-Smooth muscle
(K-SM) actin, an actin isoform of the vascular smooth muscle
cell type, has been observed to be one of the most useful
markers for myo¢broblasts since Darby et al. described that a
high proportion of ¢broblasts expressed this protein during
granulation tissue contraction [4]. Some reports illustrate that
myo¢broblasts persist under pathological circumstances, such
as a hypertrophic scar [5]. We previously reported that palatal
scar ¢broblasts possessed more myo¢broblastic characteris-
tics, including higher collagen synthesis and K-SM actin pro-
tein expression, than normal palatal ¢broblasts, and that
among a number of growth factors, transforming growth fac-
tor-L1 (TGF-L1) induced the myo¢broblastic phenotype in
normal palatal ¢broblasts [6,7]. Thus, it is conceivable that
myo¢broblasts play important roles in the palatal scar forma-
tion process.
On the other hand, the interferon family of peptides are
highly pleiotropic cytokines that exert immunomodulatory
and antiproliferative e¡ects on many cell types both in vitro
and in vivo [8]. Interferon-Q (IFN-Q) is a product of activated
T lymphocytes, macrophages, and natural killer cells. In ad-
dition to its well-recognized roles in immune and in£amma-
tory responses, IFN-Q may also in£uence the metabolism of
connective tissue cells. IFN-Q regulates collagen accumulation
by inhibiting the synthesis of type I and type III [9^11] and
abrogating the stimulatory e¡ects of TGF-L1 [12,13]. Further-
more, the anti¢brotic activity of IFN-Q was con¢rmed in vivo
[13,14].
Therefore, the aim of the present study was to examine
whether IFN-Q can modulate the myo¢broblastic phenotype
of rat palatal ¢broblasts which were induced by TGF-L1 in
vitro.
2. Materials and methods
2.1. Growth factors
Porcine TGF-L1 was purchased from RpD Systems, Inc. (Minne-
apolis, MN, USA), and rat recombinant IFN-Q was purchased from
Gibco BRL (Grand Island, NY, USA).
2.2. Cell culture
Palatal ¢broblasts were obtained from the explants of the oral
palatal mucosa of 12-week-old male Sprague-Dawley rats according
to the procedure described in previous reports [6,7]. Cells were grown
in Dulbecco’s modi¢ed Eagle’s medium (D-MEM, Gibco BRL) sup-
plemented with 10% fetal bovine serum (FBS, CSL, Ltd., Australia)
and 1% penicillin-streptomycin solution (Gibco BRL) under condi-
tions of humidi¢ed 5% CO2/95% air at 37‡C. The medium was
changed every 2^3 days, and the cells were passaged with trypsin-
EDTA (Gibco BRL) when they became con£uent. All experiments
were done using early passage cells (passage 5^10) derived from at
least three independent animals without freezing.
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2.3. Immunoblotting
Con£uent palatal ¢broblasts were pretreated with TGF-L1 (5 ng/
ml) in D-MEM containing 10% FBS for 24 h. The cultures were
washed after a 24 h exposure to TGF-L1 and then incubated with
fresh medium containing IFN-Q (1000 U/ml) for an additional 48 h.
Thereafter cells were trypsinized and counted with a hemocytometer
and then homogenized in lysing bu¡er (0.4 M Tris-HCl, 1% SDS,
0.5% DTT, 1 mM PMSF, pH 6.8) and boiled for 3 min. The protein
contents were determined using a protein quantitative assay kit (Stra-
tagene, La Jolla, CA, USA). Aliquots of 10 Wg protein from approx-
imately 2U104 cells were denatured in reducing sample bu¡er, sepa-
rated by 10% (w/v) SDS-PAGE, and transferred to PVDF membranes
(Immobilon-P, Millipore Co., Bedford, MA, USA) in transblotting
bu¡er (20 mM Tris, 150 mM glycine, 20% methanol, pH 8.0) for
16 h at 4‡C. The membranes were blocked with 5% BSA, followed
by incubation with K-SM actin-speci¢c mouse monoclonal antibodies
(1A4, ARP, Inc., Belmont, MA, USA) diluted at 1:1000 with TBS
(50 mM Tris-HCl, 150 mM NaCl, pH 7.2) containing 1% BSA and
with goat anti-mouse Ig(G+A+M) conjugated with horseradish per-
oxidase that was diluted at 1:1000 (Cappel Research Products,
Durham, NC, USA). The membranes were developed using the
ECL system (Amersham International, plc., Buckinghamshire, UK)
according to the manufacturer’s protocol. The photographic images
of the band were scanned with a color image scanner (GT-6000,
Seiko-Epson, Nagano, Japan). The integrated densities of the band
were quantitated by image analyzing computer software from NIH
Image.
2.4. Northern blot analysis
Con£uent palatal ¢broblasts were pretreated with TGF-L1 (5 ng/
ml) in D-MEM containing 10% FBS for 24 h. The culture was washed
after a 24 h exposure to TGF-L1 and then incubated with fresh me-
dium containing IFN-Q (1000 U/ml) for an additional 48 h. Thereafter
the total cellular RNA was extracted by Isogen (Wako Co., Japan).
Aliquots of total RNA (15 Wg) were electrophoresed in 1% agarose-
formaldehyde gel and blotted onto a nylon membrane (Zeta-probe,
Bio-Rad, Richmond, CA, USA) with 10USSC. Probes for proK2(I)
collagen and matrix metalloproteinase 1 (MMP1) were labeled with
[32P]dCTP (ICN Biomedicals, Inc., Costa Mesa, CA, USA) using a
Ready-To-Go DNA Labeling Kit (Pharmacia Inc., USA). Prehybrid-
ization and hybridization were performed with hybridization bu¡er
(50% formamide, 0.12 M Na2HPO4, 0.25 M NaCl, 7% SDS, 1 mM
EDTA, pH 7.2) at 43‡C. The membrane was washed in each washing
solution (2USSC/0.1% SDS, 0.5USSC/0.1% SDS, 0.1USSC/0.1%
SDS) for 15 min at room temperature and exposed to Kodak
XRP-5 ¢lm with an intensifying screen at 380‡C.
2.5. Collagen gel contraction assay
Con£uent palatal ¢broblasts were treated with 5 ng/ml of TGF-L1
in D-MEM containing 10% FBS for 24 h in the monolayer culture.
These cells were detached from the culture plates by trypsinization,
and the cell numbers were counted with a hemocytometer. Collagen
solution was prepared from a mixture of seven volumes of bovine
acid-soluble type I collagen (Cell matrix, 3 mg/ml, Nitta Gelatin
Co., Osaka, Japan), two volumes of ¢ve times concentrated
D-MEM, and one volume of pH adjusting bu¡er (0.05 M NaOH,
0.26 M NaHCO3, 0.2 M HEPES) according to the manufacturer’s
instructions. Relevant amounts of the cell suspension and FBS were
mixed into the collagen solution, and the ¢nal cell number and FBS
concentration were adjusted to 2U105/ml and 10%, respectively, to
make the total mixture. Twelve-well culture plates were precoated
with 1% Bacto agar (Difco Lab., MI, USA) to make it easier to
release the collagen gels from the wells at the beginning of the colla-
gen gel culture. 1 ml of the total mixture was dispensed into each well
of the precoated culture plates, and they were polymerized in an
atmosphere of 5% CO2/95% air at 37‡C for 30 min. Immediately after
the polymerization, 1 ml of D-MEM containing 10% FBS was added
to each well; the gels were then detached from the wells by gently
shaking the culture plates until they £oated in the medium. Collagen
gel cultures were maintained in the culture medium with or without
IFN-Q (1000 U/ml) during the experimental period. The longest and
the shortest diameters of each gel were measured at each time point,
and the mean of the two measurements was used as a parameter of
the contractility of the cells. The data represent the average diameter
þ S.E. (mm) of triplicate gels.
3. Results
3.1. IFN-Q modulates morphological change by TGF-L1 in
palatal ¢broblasts
We have previously reported that con£uent palatal ¢bro-
blasts, which exhibited a polygonal shape, became elongated
with TGF-L1 treatment in accordance with the myo¢broblas-
tic phenotype expression [7]. Therefore, we ¢rst examined the
e¡ects of IFN-Q on the morphological change induced by
TGF-L1 in palatal ¢broblasts in order to determine if IFN-Q
can change a phenotype of myo¢broblasts. Palatal ¢broblasts
were pretreated with TGF-L1 for 24 h under monolayer cul-
ture conditions, and then cells were treated with or without
IFN-Q for 48 h in the absence of TGF-L1. Con£uent palatal
¢broblasts exhibited a polygonal shape in the monolayer cul-
ture (Fig. 1a) and the palatal ¢broblasts pretreated with TGF-
L1 and without IFN-Q exhibited an elongated shape (Fig. 1b).
However, the elongated shape of the palatal ¢broblasts in-
duced by the TGF-L1 pretreatment was changed to a polyg-
onal shape by the treatment with IFN-Q (Fig. 1c).
3.2. E¡ects of IFN-Q on K-SM actin expression induced by
TGF-L1
TGF-L1 stimulates the K-SM actin expression in a variety
of cells [15,16]. We also demonstrated that TGF-L1 stimulated
the K-SM actin expression in palatal ¢broblasts [7]. Therefore,
in order to evaluate the e¡ects of IFN-Q on the TGF-L1-in-
duced K-SM actin expression in palatal ¢broblasts, we per-
formed an immunoblot study using antibodies speci¢c to
K-SM actin. Palatal ¢broblasts, which were pretreated with
5 ng/ml of TGF-L1 for 24 h, kept expressing an almost three
times higher level of K-SM actin as compared with the non-
treated palatal ¢broblasts even in the culture after the removal
of TGF-L1 for 48 h (Fig. 2A,B). When the palatal ¢broblasts,
on the other hand, were cultured with 1000 U/ml of IFN-Q for
48 h after TGF-L1 deprivation, the increment level of K-SM
actin was suppressed by approximately half as much as that
observed in the culture treated by only TGF-L1 (Fig. 2A,B).
3.3. E¡ects of IFN-Q on proK2(I) collagen and MMP1 mRNA
expression in palatal ¢broblasts
TGF-L regulates the transcription of a wide spectrum of
matrix proteins including collagen and matrix-degrading pro-
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Fig. 1. E¡ects of IFN-Q on cell morphology of palatal ¢broblasts
pretreated with TGF-L1. Palatal ¢broblasts were pretreated with
TGF-L1 (5 ng/ml) in D-MEM containing 10% FBS for 24 h and
then treated with (1000 U/ml; c) or without IFN-Q (b) for an addi-
tional 48 h. Non-treated palatal ¢broblasts showed a polygonal
shape (a). Phase contrast microscopy showed the morphological
change by TGF-L1 and IFN-Q treatment (U28).
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teinase. Therefore, we investigated the e¡ects of IFN-Q on
proK2(I) collagen and the MMP1 mRNA expression in pala-
tal ¢broblasts. When palatal ¢broblasts were treated with
(Fig. 3, lane b) or without (Fig. 3, lane a) TGF-L1 (5 ng/
ml) for 24 h, the proK2(I) collagen mRNA expression was
enhanced, and the MMP1 mRNA expression was inhibited
by TGF-L1 treatment. Subsequent to the 24 h of TGF-L1
pretreatment, the palatal ¢broblasts were cultured in the fresh
medium with (Fig. 3, lane d) or without (Fig. 3, lane c) IFN-Q
(1000 U/ml) for 48 h in the absence of TGF-L1, and a North-
ern blot analysis was then performed. IFN-Q treatment inhib-
ited the proK2(I) collagen mRNA expression induced by the
TGF-L1 pretreatment, but appeared to have no e¡ects on the
MMP1 mRNA expression in the palatal ¢broblasts.
3.4. IFN-Q modulates contractility of myo¢broblastic phenotype
induced by TGF-L1
We previously demonstrated that palatal ¢broblasts with
TGF-L1 pretreatment for 24 h showed high contractility as
compared with the non-treated palatal ¢broblasts. In order to
clarify the e¡ects of IFN-Q on cell contractility, we investi-
gated whether IFN-Q inhibited the contractility of palatal ¢-
broblasts stimulated by the TGF-L1 pretreatment. Monolayer
palatal ¢broblasts were pretreated with or without TGF-L1 (5
ng/ml) for 24 h, after which they were transferred to a colla-
gen gel culture system. Palatal ¢broblasts with the TGF-L1
pretreatment (Fig. 4, E) showed a remarkably high contrac-
tility as compared with the palatal ¢broblasts without the
TGF-L1 pretreatment (Fig. 4, a) through the 96 h culture
period. When IFN-Q (1000 U/ml, Fig. 4, O) was administered
to the collagen gel culture, the contractility enhancement of
the palatal ¢broblasts with the TGF-L1 pretreatment was par-
tially blocked.
4. Discussion
The TGF-L family is a multifunctional regulator of cell
growth, di¡erentiation and extracellular matrix deposition in-
cluding type I collagen [17]. Recently, it was reported that
neutralization of TGF-L1 and TGF-L2 reduced scarring in
rat cutaneous wounds [18]. Similar preventive e¡ects of neu-
tralizing antibodies or antagonists to TGF-L1 on other ¢-
brotic diseases have been reported [19^22]. Thus, TGF-L1 is
implicated in pathogenic ¢brotic conditions and scarring of
skin wounds. We previously reported that TGF-L1 induced
K-SM actin expression and collagen synthesis in palatal ¢bro-
blasts and plays an important role in the expression of the
myo¢broblastic phenotype [6,7]. In order to easily evaluate
whether IFN-Q can regulate myo¢broblastic di¡erentiation in
this study, we preconditioned palatal ¢broblast cultures by
administering TGF-L1 to them for 24 h, because palatal ¢-
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Fig. 2. K-SM actin expression was detected by immunoblot analysis.
A: Palatal ¢broblasts were pretreated with TGF-L1 in D-MEM
containing 10% FBS for 24 h and then treated with (1000 U/ml,
lane c) or without IFN-Q (lane b) for an additional 48 h. Cell ly-
sates were prepared and subjected to 10% SDS-PAGE (10 Wg pro-
tein/lane), followed by immunoblotting with anti-K-SM actin mono-
clonal antibody. IFN-Q decreased the expression of K-SM actin
protein enhanced by the TGF-L1 pretreatment. Non-treated palatal
¢broblasts are shown in lane a. B: The integrated density of the
band was quantitated by scanning densitometry.
Fig. 3. ProK2(I) collagen and matrix metalloproteinase 1 (MMP1)
mRNA expression in palatal ¢broblasts analyzed by Northern blot.
When the palatal ¢broblasts were treated with (lane b) or without
(lane a) TGF-L1 treatment for 24 h, proK2(I) collagen mRNA ex-
pression was enhanced, and MMP1 mRNA expression was inhibited
by the TGF-L1 treatment. Subsequent to 24 h of the TGF-L1 pre-
treatment, palatal ¢broblasts were cultured in fresh medium with
(lane d) or without (lane c) 1000 U/ml IFN-Q for 48 h in the ab-
sence of TGF-L1. IFN-Q signi¢cantly inhibited proK2(I) collagen
mRNA expression, whereas it did not change MMP1 mRNA ex-
pression in the palatal ¢broblasts. Ethidium bromide stainings of
the corresponding gels are shown in the lower panels.
Fig. 4. E¡ects of IFN-Q on contractility of the myo¢broblastic phe-
notype induced by TGF-L1. Monolayer palatal ¢broblasts were
treated with or without TGF-L1 (5 ng/ml) for 24 h, and then were
transferred to the collagen gel culture system. The TGF-L1-pre-
treated palatal ¢broblasts (E) showed a remarkably high contractil-
ity as compared to the non-treated palatal ¢broblasts (a) through
the 96 h culture period. When IFN-Q (1000 U/ml, O) was adminis-
tered to the collagen gel culture, the contractility enhancement of
the TGF-L1-pretreated palatal ¢broblasts was partially blocked.
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broblasts hardly expressed the K-SM actin protein and pro-
K2(I) collagen mRNA. By administering TGF-L1 to this cul-
ture for 24 h, the palatal ¢broblasts were made to express the
K-SM actin protein and proK2(I) collagen mRNA much more
strongly than palatal ¢broblasts without TGF-L1 treatment.
Recently, with a combined immunohistochemical and in situ
hybridization study, it has been shown that K-SM actin-ex-
pressing myo¢broblasts are the main producer of collagen
during pulmonary ¢brosis [23], which agreed with our results.
We showed in the present study that IFN-Q decreased up to
approximately 50% the K-SM actin expression induced by
TGF-L1. Similarly, inhibition of the K-SM actin expression
has also been reported in other cell types, such as rat dermal
¢broblasts [24] and smooth muscle cells [25]. These results
suggested that IFN-Q is a potential inhibitor of myo¢broblas-
tic di¡erentiation. As for the mechanism by which IFN-Q
downregulates K-SM actin expression, it was recently reported
that NO-dependent increases in the cellular cGMP levels me-
diate the inhibitory e¡ect of IFN-Q on K-SM actin expression
in rat hepatic stellate cells [26].
Wound healing is an orderly process that involves in£am-
mation, reepithelialization, matrix deposition, and tissue re-
modeling. MMPs that degrade various extracellular matrices
are required to remove damaged tissue and the provisional
matrix, and MMP1 in particular, seems to play a critical
role in various stages of the wound healing process. Regula-
tion of MMP1 expression is cell type-speci¢c, as demonstrated
by the fact that TGF-L repressed the basal and TNF-K in-
duced MMP1 gene expression in dermal ¢broblasts, whereas
it activated its expression in epidermal keratinocytes [27]. Our
result showed that TGF-L1 inhibited MMP1 gene expression
in palatal ¢broblasts, whereas IFN-Q had no e¡ect on its gene
expression. Our results are not consistent with previous re-
ports that IFN-Q prevented MMP1 gene expression in human
dermal ¢broblasts [28], but we con¢rmed that IFN-Q de-
creased its gene expression in palatal ¢broblasts without
TGF-L1 pretreatment (data not shown). The TGF-L1 pre-
treatment may be responsible for the diverse e¡ects of IFN-
Q on MMP1 gene expression.
The three-dimensional collagen gel culture system has been
developed to study wound contraction in vivo [29]. Contrac-
tility in collagen gel has been reported to be enhanced by
serum or puri¢ed growth factors, such as TGF-L [30^32].
We have shown in the present study that IFN-Q inhibited
the high contractility induced by TGF-L1 pretreatment in pal-
atal ¢broblasts. These results are consistent with previous re-
ports [33,34]. The e¡ects of IFN-Q were totally independent of
any alteration of cell number or viability. The mechanism of
inhibition might be related either to a decreased expression of
cell adhesion molecules on the cell surface or to a decreased
cell locomotion or cell contraction forces.
Taken together, we demonstrated that IFN-Q partially ab-
rogated myo¢broblastic phenotype expression, including
K-SM actin, proK2(I) collagen mRNA expression and cell
contractility, induced by TGF-L1 in vitro and might become
a therapeutic agent to block scarring in oral palatal mucosa in
the future.
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